Hepatitis Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatitis C Virus Therapy
Data from University of Paris, Department of Virology advance knowledge in hepatitis C virus therapy
August 6th, 2007
A new study, "Analysis of ribavirin mutagenicity in human hepatitis C virus infection," is now available. "The addition of ribavirin to alpha interferon therapy significantly increases response rates for patients with chronic hepatitis C virus (HCV) infection, but ribavirin's antiviral mechanisms are unknown. Ribavirin has been suggested to have mutagenic potential in vitro that would lead to "error catastrophe," i.e., the generation of nonviable viral quasispecies due to the increment in the number of mutant genomes, which prevents the transmission of meaningful genetic information," scientists in Creteil, France report. "We used extensive sequence-based analysis of...
Source: Hepatitis Weekly (2007-08-06)
|
